R
Ron Paquette
Researcher at University of California, Los Angeles
Publications - 20
Citations - 5964
Ron Paquette is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 11, co-authored 20 publications receiving 5700 citations. Previous affiliations of Ron Paquette include UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Mercedes E. Gorre,Mansoor Mohammed,Katharine Ellwood,Nicholas C. Hsu,Ron Paquette,P. Nagesh Rao,Charles L. Sawyers +6 more
TL;DR: It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Journal ArticleDOI
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz,Neil P. Shah,Hagop M. Kantarjian,Nicholas J. Donato,John Nicoll,Ron Paquette,Jorge E. Cortes,Susan O'Brien,Claude Nicaise,Eric Bleickardt,M. Anne Blackwood-Chirchir,Vishwanath Iyer,Tai-Tsang Chen,Fei Huang,Arthur P. DeCillis,Charles L. Sawyers,Charles L. Sawyers +16 more
TL;DR: Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs.
Journal ArticleDOI
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Kimmo Porkka,Perttu Koskenvesa,Tuija Lundán,Johanna Rimpiläinen,Satu Mustjoki,Richard Smykla,Robert A. Wild,Roger Luo,Montserrat Arnan,Benoit Brethon,Lydia Eccersley,Henrik Hjorth-Hansen,Martin Höglund,Hana Klamova,Håvar Knutsen,Suhag Parikh,Emmanuel Raffoux,Franz Gruber,Finella Brito-Babapulle,Hervé Dombret,Rafael F. Duarte,Erkki Elonen,Ron Paquette,C. Michel Zwaan,Francis Y. Lee +24 more
TL;DR: Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clinical activity in patients who experience CNS relapse while on imatinib therapy.
Journal Article
An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients
Anne Marie O'Farrell,James M. Foran,Walter Fiedler,Hubert Serve,Ron Paquette,Maureen Cooper,Helene A. Yuen,Sharianne G. Louie,Heidi Kim,Susan L Nicholas,Michael Heinrich,Wolfgang E. Berdel,Carlo L. Bello,Mark Jacobs,Paul Scigalla,William C. Manning,Stephen Kelsey,Julie M. Cherrington +17 more
TL;DR: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients and accomplishes a crucial milestone in the development of novel oncology therapeutics.
Journal ArticleDOI
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
Hagop M. Kantarjian,Francis J. Giles,Peter L. Greenberg,Ron Paquette,Eunice S. Wang,Janice Gabrilove,Guillermo Garcia-Manero,Kuolung Hu,Janet Franklin,Dietmar Berger +9 more
TL;DR: It is suggested romiplostim may provide clinical benefits in MDS patients during azacitidine therapy and significantly raised median platelet counts during cycle 3 on day 1 and at the nadir compared with placebo.